Diamyd Medical AB (publ) Market Cap ($16.14 Million)
Market Cap & Net Worth: Diamyd Medical AB (publ) (DMYD-B)
Diamyd Medical AB (publ) market cap. Diamyd Medical AB (publ) (ST:DMYD-B) has a market capitalization of $16.14 Million (Skr149.97 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #25601 globally and #517 in its home market, demonstrating a -1.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Diamyd Medical AB (publ)'s stock price Skr0.99 by its total outstanding shares 151481380 (151.48 Million). Also see Diamyd Medical AB (publ) cash flow conversion for how efficiently the company converts equity into cash flow.
Diamyd Medical AB (publ) Market Cap History (2015–2026)
Diamyd Medical AB (publ) market cap history from 2015 to 2026. Data shows change from $96.18 Million to $16.14 Million (-16.99% CAGR). Check today's stock price for Diamyd Medical AB (publ) for real-time trading data and today's change.
Index Memberships
Diamyd Medical AB (publ) is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.29 Billion | 0.11% | #118 of 281 |
Weight: Diamyd Medical AB (publ)'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Diamyd Medical AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Diamyd Medical AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore DMYD-B net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1411.99x
Diamyd Medical AB (publ)'s market cap is 1411.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $106.78 Million | $757.00K | -$32.01 Million | 141.05x | N/A |
| 2017 | $55.10 Million | $922.00K | -$25.55 Million | 59.76x | N/A |
| 2018 | $112.48 Million | $726.00K | -$43.95 Million | 154.93x | N/A |
| 2019 | $405.92 Million | $1.57 Million | -$36.73 Million | 258.87x | N/A |
| 2020 | $502.91 Million | $341.00K | $9.71 Million | 1474.81x | 51.80x |
| 2021 | $241.27 Million | $253.00K | $60.05 Million | 953.62x | 4.02x |
| 2022 | $217.96 Million | $454.00K | -$103.52 Million | 480.08x | N/A |
| 2023 | $107.10 Million | $546.00K | -$116.07 Million | 196.16x | N/A |
| 2024 | $268.00 Million | $130.00K | -$151.85 Million | 2061.55x | N/A |
| 2025 | $183.56 Million | $130.00K | -$169.78 Million | 1411.99x | N/A |
Competitor Companies of DMYD-B by Market Capitalization
Companies near Diamyd Medical AB (publ) in the global market cap rankings as of November 4, 2026. Also see Diamyd Medical AB (publ) total assets for a full breakdown of the balance sheet.
Key companies related to Diamyd Medical AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Diamyd Medical AB (publ) (2015–2026)
Market capitalization of Diamyd Medical AB (publ) from 2015 to today. Between 2015 and today, Diamyd Medical AB (publ)'s market cap moved from $96.18 Million to $ 16.14 Million, with a yearly change of -16.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr16.14 Million | -91.21% |
| 2025 | Skr183.56 Million | -31.51% |
| 2024 | Skr268.00 Million | +150.23% |
| 2023 | Skr107.10 Million | -50.86% |
| 2022 | Skr217.96 Million | -9.66% |
| 2021 | Skr241.27 Million | -52.03% |
| 2020 | Skr502.91 Million | +23.90% |
| 2019 | Skr405.92 Million | +260.87% |
| 2018 | Skr112.48 Million | +104.14% |
| 2017 | Skr55.10 Million | -48.40% |
| 2016 | Skr106.78 Million | +11.02% |
| 2015 | Skr96.18 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Diamyd Medical AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.14 Million USD |
| MoneyControl | $16.14 Million USD |
| MarketWatch | $16.14 Million USD |
| marketcap.company | $16.14 Million USD |
| Reuters | $16.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more